CY1117816T1 - Φαρμακευτικη συνθεση περιεχουσα σολιφενακινη - Google Patents

Φαρμακευτικη συνθεση περιεχουσα σολιφενακινη

Info

Publication number
CY1117816T1
CY1117816T1 CY20161100678T CY161100678T CY1117816T1 CY 1117816 T1 CY1117816 T1 CY 1117816T1 CY 20161100678 T CY20161100678 T CY 20161100678T CY 161100678 T CY161100678 T CY 161100678T CY 1117816 T1 CY1117816 T1 CY 1117816T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical composition
solifenakin
content
solifenacin
acrylic
Prior art date
Application number
CY20161100678T
Other languages
English (en)
Inventor
Tatsunobu Yoshioka
Makoto Murai
Hiroaki Tasaki
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of CY1117816T1 publication Critical patent/CY1117816T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Εδώ αποκαλύπτεται μια φαρμακευτική σύνθεση περιλαμβάνουσα ένα σύμπλοκο μεταξύ σολιφενακίνης ή ενός φαρμακευτικώς αποδεκτού άλατος αυτής και μιας ιοντοανταλλακτικής ρητίνης, και ένα βασιζόμενο σε ακρυλικό πολυμερές.
CY20161100678T 2010-05-19 2016-07-14 Φαρμακευτικη συνθεση περιεχουσα σολιφενακινη CY1117816T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34631110P 2010-05-19 2010-05-19
PCT/JP2011/061376 WO2011145642A1 (ja) 2010-05-19 2011-05-18 ソリフェナシン含有医薬組成物

Publications (1)

Publication Number Publication Date
CY1117816T1 true CY1117816T1 (el) 2017-05-17

Family

ID=44972988

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100678T CY1117816T1 (el) 2010-05-19 2016-07-14 Φαρμακευτικη συνθεση περιεχουσα σολιφενακινη

Country Status (23)

Country Link
US (1) US9918970B2 (el)
EP (1) EP2572717B1 (el)
JP (1) JP5831449B2 (el)
KR (1) KR20130093010A (el)
CN (1) CN102905706A (el)
AU (1) AU2011255951C1 (el)
BR (1) BR112012029461A2 (el)
CA (1) CA2799942C (el)
CY (1) CY1117816T1 (el)
EA (1) EA023294B1 (el)
ES (1) ES2588008T3 (el)
HR (1) HRP20160901T1 (el)
HU (1) HUE029400T2 (el)
IL (1) IL223113A0 (el)
LT (1) LT2572717T (el)
MX (1) MX2012013328A (el)
PL (1) PL2572717T3 (el)
PT (1) PT2572717T (el)
RS (1) RS55044B1 (el)
SI (1) SI2572717T1 (el)
TW (1) TW201208684A (el)
WO (1) WO2011145642A1 (el)
ZA (1) ZA201208762B (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2942063A1 (en) 2014-05-06 2015-11-11 S.I.I.T. S.r.L. - Unipersonale Composition for fluidizing mucus comprising chitosan and copolymers
CN104133011A (zh) * 2014-07-01 2014-11-05 北京万全德众医药生物技术有限公司 液相色谱法分离分析琥珀酸索利那新中间体及其有关物质
US20200022910A1 (en) 2017-02-24 2020-01-23 Ftf Pharma Private Limited Pharmaceutical composition of oral solution of muscarinic antagonist
UY38137A (es) * 2018-03-08 2019-07-31 Intas Third Party Sales 2005 S L Una forma de dosificación oral sólida farmacéutica de solifenacina
KR20210114271A (ko) 2020-03-10 2021-09-23 주식회사 종근당 솔리페나신 또는 이의 약제학적으로 허용가능한 염을 함유하는 약제학적 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554367A (en) * 1984-10-31 1996-09-10 Alcon Laboratories, Inc. Compositions for treatment of glaucoma
JP3207494B2 (ja) * 1992-04-02 2001-09-10 ロート製薬株式会社 水性懸濁製剤
JPH075604A (ja) * 1993-06-18 1995-01-10 Konica Corp ハロゲン化銀写真感光材料
GB9402029D0 (en) 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
JP2003504416A (ja) * 1999-07-14 2003-02-04 シェーリング−プラウ・リミテッド イオン交換樹脂を使用する経口キノロン液状製剤の味覚マスキング
US7001615B1 (en) * 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
DE10224086A1 (de) * 2002-05-31 2003-12-11 Bayer Ag Pharmazeutische Zubereitungen zur oralen Anwendung enthaltend wirkstoffbeladene Ionentauscherharze sowie strukturviskose Gelbildner als Verdicker
KR20070010132A (ko) 2004-03-25 2007-01-22 아스텔라스세이야쿠 가부시키가이샤 솔리페나신 또는 그의 염의 고형 제제용 조성물
CA2591761A1 (en) * 2004-12-27 2006-07-06 Astellas Pharma Inc. Stable particulate pharmaceutical composition of solifenacin or salt thereof
EP2146693A2 (en) * 2007-04-11 2010-01-27 Dr. Reddy's Laboratories Ltd. Solifenacin compositions

Also Published As

Publication number Publication date
US9918970B2 (en) 2018-03-20
EP2572717A4 (en) 2013-11-20
TW201208684A (en) 2012-03-01
WO2011145642A1 (ja) 2011-11-24
PT2572717T (pt) 2016-07-19
AU2011255951B2 (en) 2014-08-14
SI2572717T1 (sl) 2016-11-30
JPWO2011145642A1 (ja) 2013-07-22
HRP20160901T1 (hr) 2016-10-07
CN102905706A (zh) 2013-01-30
CA2799942C (en) 2018-07-17
EP2572717B1 (en) 2016-06-15
CA2799942A1 (en) 2011-11-24
AU2011255951A1 (en) 2012-12-20
EA023294B1 (ru) 2016-05-31
IL223113A0 (en) 2013-02-03
RS55044B1 (sr) 2016-12-30
EP2572717A1 (en) 2013-03-27
MX2012013328A (es) 2013-02-01
AU2011255951C1 (en) 2015-02-19
EA201291276A1 (ru) 2013-05-30
US20110288118A1 (en) 2011-11-24
LT2572717T (lt) 2016-09-26
ZA201208762B (en) 2014-02-26
BR112012029461A2 (pt) 2017-03-01
PL2572717T3 (pl) 2016-12-30
ES2588008T3 (es) 2016-10-28
JP5831449B2 (ja) 2015-12-09
KR20130093010A (ko) 2013-08-21
HUE029400T2 (en) 2017-03-28

Similar Documents

Publication Publication Date Title
CY1121712T1 (el) Γελη λυματος αιμοπεταλιων
CY1124810T1 (el) Συνδυαστικη θεραπεια για τη θεραπευτικη αντιμετωπιση του καρκινου
CY1117816T1 (el) Φαρμακευτικη συνθεση περιεχουσα σολιφενακινη
CY1121849T1 (el) Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CY1120480T1 (el) Ενωσεις πυραζολοπυριμιδινης
CY1121150T1 (el) Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας
CY1118695T1 (el) Αναστολεις απομεθυλασων ιστονων
CY1124331T1 (el) Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης
CY1117424T1 (el) Βενζοδιαζεπινικος αναστολεας bromodomain
CY1118839T1 (el) Επικαλυμμενη φαρμακευτικη συνθεση που περιεχει ρεγοραφενιμπη
CY1116645T1 (el) Ενωση-αναστολεας σηματοδοτικου μονοπατιου notch
BR112015022674A2 (pt) inibidores de bromodomínio
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
BR112013020675A2 (pt) dispositivos, sistemas e métodos para avaliação de hemostasia
BR112015032710A2 (pt) inibidores de bromodomínio
CY1121631T1 (el) Ενωση πυραζολης και φαρμακευτικη χρηση εξ αυτης
EA201400986A1 (ru) Фармацевтические композиции, содержащие метформин и ингибитор dpp-4 или ингибитор sglt-2
BR112013010834A2 (pt) polipeptídeos fator ix modificados e usos dos mesmos
CL2013003450A1 (es) Composicion que contiene oxintomodulina, un polimero de polietilenglicol y 9-fluorenilmetoxicarbonilo o 2-sulfo-9-fluorenilmetoxicarbonilo; metodos de uso.
CY1121829T1 (el) Κατιονικα πολυμερη που εχουν τη βαση τους στο γλυκογονο
DK3384903T3 (da) Mikropartikelholdigt terapeutisk protein coatet med biologisk nedbrydelig polymer til medicinsk anvendelse
EA201491447A1 (ru) Ендиины, их конъюгаты и способы их получения и применения
TR201905683T4 (tr) Aşındırıcı presbiyopi için oftalmik formülasyon ve yöntem.
BR112014025041B8 (pt) Composição farmacêutica